<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316717</url>
  </required_header>
  <id_info>
    <org_study_id>IMM-124E-2001</org_study_id>
    <nct_id>NCT02316717</nct_id>
  </id_info>
  <brief_title>A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis</brief_title>
  <official_title>A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immuron Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immuron Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and preliminary efficacy of two dose levels of IMM-124E
      in reducing liver fat and/or serum alanine aminotransaminase (ALT) compared with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who provide voluntary written informed consent will be screened for eligibility.
      Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to
      participate.

      Eligible subjects will be randomized at the Baseline visit to receive one of the three study
      treatments three times daily for a period of 24 weeks. Each subject will return to the study
      clinic for assessment and required study procedures on Day 7, 14 and 28 and every 4 weeks
      thereafter until Week 24.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Outcome Measure</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Incidence of adverse events per arm/group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Fat Content of the Liver</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Mean change from Baseline in Percentage Fat Content of the Liver measured by Magnetic Resonance Imaging (MRI) at Week 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of patients with treatment-related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of grade 3-5 adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Mean change in Systolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Mean change in Pulse Rate from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change in Diastolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Mean change in Respiratory Rate from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Alanine Aminotransaminase (ALT)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Mean change from Baseline in Serum Alanine Aminotransaminase (ALT) at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Serum Concentration (Cmax)</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Peak serum concentration (Cmax) of IMM-124E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin)</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Minimum serum concentration (Cmin) of IMM-124E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve (AUC)</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Area Under the Concentration Time Curve (AUC) of IMM-124E. Time points at which data were collected: baseline pre-dose, week 4, week 12 and week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Life (T1/2)</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Elimination Half Life (T1/2) of IMM-124E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Body Mass Index (BMI) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Waist Circumference at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist:Hip Ratio</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Waist:Hip Ratio at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (HB)A1C</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Hemoglobin(HB)A1C at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>baseline and 24 Weeks</time_frame>
    <description>Change from Baseline of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Total Cholesterol at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Triglycerides at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein (LDL)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Low Density Lipoprotein (LDL) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein (HDL)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of High Density Lipoprotein (HDL) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Alanine Aminotransaminase (ALT)</measure>
    <time_frame>baseline to 24 weeks</time_frame>
    <description>Mean change from Baseline of serum ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Aspartate Aminotransaminase (AST)</measure>
    <time_frame>baseline to 24 Weeks</time_frame>
    <description>Mean change from Baseline of Serum AST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>baseline to 24 Weeks</time_frame>
    <description>Mean change from Baseline of Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>baseline to 24 Weeks</time_frame>
    <description>Mean change from Baseline of Albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma Glutamyl Transpeptidase (GGT)</measure>
    <time_frame>baseline to 24 Weeks</time_frame>
    <description>Mean change from Baseline of Gamma Glutamyl Transpeptidase (GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Alanine Aminotransaminase (ALT)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Number of patients with ALT within the normal reference range at Week 24 (defined a &lt;19 IU/L for women and &lt;30 IU/L for men)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Concentrations of Lipopolysaccharide (LPS)</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>The percentage of subjects reporting at least 15% reduction in LPS, from baseline to Week 24</description>
  </other_outcome>
  <other_outcome>
    <measure>Regulatory T Cells (FoxP3+ CD25-CD4+) in Peripheral Blood Mononuclear Cells</measure>
    <time_frame>0 and 24 Weeks</time_frame>
    <description>Change in percent of FoxP3+ CD25-CD4+ cells in Peripheral Blood Mononuclear Cells</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut Microbiome From Fecal Samples</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Number of participants with measurable differences in gut microbiome constituents post-treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Concentrations of LPS</measure>
    <time_frame>baseline to 24 Weeks</time_frame>
    <description>Serum Concentrations of Lipopolysaccharide (LPS) (ng/mL) levels and change from Baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Concentrations of C-Reactive Protein (CRP)</measure>
    <time_frame>baseline to 24 Weeks</time_frame>
    <description>Mean Serum Concentrations of C-Reactive Protein (CRP) at week 24</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Concentrations of CK-18 Fragments</measure>
    <time_frame>baseline to 24 weeks</time_frame>
    <description>The proportion of subjects with significant reduction of CK-18 (≥ 15%) between IMP 1200mg group to placebo.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Concentrations of Human Adiponectin</measure>
    <time_frame>0 to 24 Weeks</time_frame>
    <description>Change from Run-in to Post-treatment in serum concentration of human Adiponectin.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Concentrations of Cytokine IL-6</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean Change from baseline to week 24 of serum concentration of cytokine IL-6</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Concentration of Cytokine IL-12p70</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean change from baseline to week 24 of Serum concentration of Cytokine IL-12p70</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Concentration of Interferon Gamma (IFN-γ)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean Change from baseline to week 24 of serum concentration of IFN-gamma</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Concentration of Tumor Necrosis Factor Alpha (TNF-α)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean Change from baseline to week 24 of serum concentration of TNF-α</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Concentration of Glucagon-like Peptide-1 (GLP-1)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean Change from baseline to week 24 of serum concentration of GLP-1</description>
  </other_outcome>
  <other_outcome>
    <measure>Regulatory T Cells (FoxP3+CD25-CD8+) in Peripheral Blood Mononuclear Cells</measure>
    <time_frame>0 and 24 Weeks</time_frame>
    <description>Change in percent of FoxP3+CD25-CD8+ cells in Peripheral Blood Mononuclear Cells</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Non-alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM-124E, 600 mg three times daily, orally plus matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM-124E, 1200 mg three times daily, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, three times daily, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMM-124E</intervention_name>
    <description>IMM-124E</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Treatment Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years.

          2. Provision of written informed consent.

          3. Diagnosis of NASH, histologically proven within 12 months of Screening with

               -  NASH activity score (NAS) of 4 or more

               -  cytologic ballooning score of at least 1;

               -  10% or more macrovescicular steatosis.

               -  Hematoxylin &amp; Eosin (H&amp;E) stained slides and/or paraffin block available for
                  independent assessment.

          4. HBA1C of &lt;9.0

          5. Agree to the use of effective contraceptive measures if either male or female of child
             bearing potential.

        Exclusion Criteria:

          1. Presence of vascular liver disease or cirrhosis;

          2. Presence of liver disease with other cause (autoimmune, metabolic, medication
             induced);

          3. BMI &lt;25 kg/m^2;

          4. Alcohol use &gt;30 g/day;

          5. Type 1 diabetes;

          6. 6. History of major bariatric surgery (not including balloon / sleeve gastrectomy);

          7. Weight loss or gain of 5kg or more in the past 6 months or &gt;10% change in bodyweight
             in the past 12 months;

          8. Contraindication for MRI;

          9. Inadequate venous access;

         10. Lactating/breastfeeding/pregnant at Screening or Baseline;

         11. HIV antibody positive, hepatitis B surface antigen positive (HBsAg) or Hepatitis C
             virus (HCV)-RNA positive;

         12. Receiving an elemental diet or parenteral nutrition;

         13. Concurrent conditions

               -  Inflammatory bowel disease;

               -  Unstable angina, myocardial infarction, transient ischemic events, or stroke
                  within 24 weeks of Screening;

               -  Ongoing infectious, ongoing multi-systemic immune-mediated and/or concurrent or
                  past malignant disease;

               -  Any other concurrent condition which, in the opinion of the investigator, could
                  impact adversely on the subject participating or on the interpretation of the
                  study data;

         14. Concurrent medications including:

               -  anti-NASH therapy(s) taken for more than 10 continuous days in the last 3 months.
                  These include S-adenosyl methionine (SAM-e), betaine, milk thistle, probiotic
                  supplements (other than yoghurt), vitamin E and gemfibrozil.

                    -  NB: If vitamin E or gemfibrozil are used, the dose must be stable and liver
                       biopsy confirming diagnosis of NASH subsequent to commencing treatment;
                       commencing treatment;

                    -  Wash out for any of the anti-NASH therapies is as follows: under 10 days no
                       washout required, more than 10 days and up to 3 months treatment requires 6
                       weeks washout. Any treatment of over 3 months would require to re-biopsy to
                       ensure histological eligibility

               -  thiazolidinediones (glitazones), dipeptidyl peptidase 4 inhibitors (gliptins) or
                  glucagon-like peptide-1 analogs in the last 6 months. If treatment commenced and
                  is stable for more than 6 month prior to the determinant biopsy and the dose is
                  still stable at time of study entry, subjects will be eligible for recruitment.

               -  Allowable anti-diabetic treatment includes metformin and/or sulfonylureas
                  administered at constant dose for at least 2 months prior to study entry.

               -  Subjects treated with Insulin are eligible if clinically stable on insulin
                  treatment (i.e. no recurrent acute hypo-/hyperglycemic episodes diagnosed
                  clinically and by Glucose serum levels of &lt;50 mg/dL and &gt;200 mg/dL respectively)
                  for at least 2 months prior to study entry.

               -  immune modulatory agents including

                    -  In the last 3 months:

                    -  systemic steroids for more than 7 days.

                    -  daily treatment with multiple non-steroidal anti-inflammatory drugs (such as
                       aspirin &gt;100mg/day, ibuprofen, naproxen, meloxicam, celecoxib) for more than
                       1 month within 3 months prior to study entry;

                    -  In the last 12 months:

                    -  azathioprine, 6-mercaptopurine, methotrexate, cyclosporin, anti-TNFα
                       therapies (infliximab, adalimumab, etanercept) or anti-integrin therapies
                       (namixilab) ;

               -  more than 10 consecutive days oral or parenteral antibiotics within 4 weeks prior
                  to study entry (Note: such subjects would not be included in the stool and PBMC
                  analysis).

               -  variable dose of antilipidemic agents (3-hydroxy-3-methyl-glutaryl (HMG)-Co-A
                  reductase inhibitors - &quot;statins&quot;) in the 3 months prior to study entry.

         15. The following laboratory abnormalities:

               -  Neutrophil count ≤1.0 x 10^9/L

               -  Platelets &lt;100 x 10^9/L

               -  Hemoglobin &lt;10 g/dL

               -  Albumin &lt;3.5 g/dL

               -  International Normalized Ratio (INR) &gt;1.5

               -  Total bilirubin &gt;1.5 x upper limit of reference range (unless Gilbert's syndrome
                  or extrahepatic source as denoted by increased indirect bilirubin fraction)

               -  Either creatinine clearance ≤60 mL/minute calculated by Cockroft Gault or
                  creatinine &gt;1.5x upper limit of reference range.

         16. Known substance abuse, including inhaled or injected drugs in the year prior to
             Screening.

         17. Cow milk allergy, lactose intolerance or any known or suspected hypersensitivity to
             study products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Peres</last_name>
    <role>Study Director</role>
    <affiliation>Immuron Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Hepatology Research at CTRB</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Liver Centre</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor St Lukes Medical Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Medical Centre</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Immaculate Hospital</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours St Marys Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Centre</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Nepean Hospital</name>
      <address>
        <city>Penrith</city>
        <state>New South Wales</state>
        <zip>2750</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Centre</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center (Ichilov)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <results_first_submitted>January 7, 2020</results_first_submitted>
  <results_first_submitted_qc>February 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2020</results_first_posted>
  <last_update_submitted>February 8, 2020</last_update_submitted>
  <last_update_submitted_qc>February 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02316717/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02316717/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm A</title>
          <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
        </group>
        <group group_id="P2">
          <title>Treatment Arm B</title>
          <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
        </group>
        <group group_id="P3">
          <title>Treatment Arm C</title>
          <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>TBC</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm A</title>
          <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
        </group>
        <group group_id="B2">
          <title>Treatment Arm B</title>
          <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
        </group>
        <group group_id="B3">
          <title>Treatment Arm C</title>
          <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="133"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.4" spread="11.9"/>
                    <measurement group_id="B2" value="50.2" spread="13.7"/>
                    <measurement group_id="B3" value="50.2" spread="11.1"/>
                    <measurement group_id="B4" value="50.59" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.97" spread="5.439"/>
                    <measurement group_id="B2" value="34.12" spread="5.802"/>
                    <measurement group_id="B3" value="34.54" spread="5.678"/>
                    <measurement group_id="B4" value="34.21" spread="5.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.14" spread="0.765"/>
                    <measurement group_id="B2" value="6.16" spread="0.999"/>
                    <measurement group_id="B3" value="6.12" spread="0.916"/>
                    <measurement group_id="B4" value="6.141" spread="0.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatic Fat</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.64" spread="9.237"/>
                    <measurement group_id="B2" value="19.11" spread="8.166"/>
                    <measurement group_id="B3" value="18.39" spread="7.067"/>
                    <measurement group_id="B4" value="19.04" spread="8.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Outcome Measure</title>
        <description>Incidence of adverse events per arm/group</description>
        <time_frame>24 Weeks</time_frame>
        <population>Number of treatment emerged AEs per arm/group</population>
        <group_list>
          <group group_id="O1">
            <title>IMM-124E, 600 mg</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo 24 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>IMM-124E, 1200 mg</title>
            <description>IMM-124E, 1200 mg three times daily, orally 24 weeks of treatment</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo</title>
            <description>Matching placebo, three times daily, orally 24 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome Measure</title>
          <description>Incidence of adverse events per arm/group</description>
          <population>Number of treatment emerged AEs per arm/group</population>
          <units>AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="207"/>
                    <measurement group_id="O3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Fat Content of the Liver</title>
        <description>Mean change from Baseline in Percentage Fat Content of the Liver measured by Magnetic Resonance Imaging (MRI) at Week 24</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>The analysis population includes subjects with both baseline MRI and week 24 MRI.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Fat Content of the Liver</title>
          <description>Mean change from Baseline in Percentage Fat Content of the Liver measured by Magnetic Resonance Imaging (MRI) at Week 24</description>
          <population>The analysis population includes subjects with both baseline MRI and week 24 MRI.</population>
          <units>percentage of hepatic fat fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="0.903"/>
                    <measurement group_id="O2" value="-0.90" spread="0.818"/>
                    <measurement group_id="O3" value="-1.85" spread="0.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Number of patients with treatment-related adverse events</description>
        <time_frame>24 weeks</time_frame>
        <population>Number of patients with any treatment-related AE</population>
        <group_list>
          <group group_id="O1">
            <title>IMM-124E, 600 mg</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo 24 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>IMM-124E, 1200 mg</title>
            <description>IMM-124E, 1200 mg three times daily, orally 24 weeks of treatment</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo</title>
            <description>Matching placebo, three times daily, orally 24 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of patients with treatment-related adverse events</description>
          <population>Number of patients with any treatment-related AE</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severity of Adverse Events</title>
        <description>Number of grade 3-5 adverse events</description>
        <time_frame>24 weeks</time_frame>
        <population>Number of grade 3-5 AEs</population>
        <group_list>
          <group group_id="O1">
            <title>IMM-124E, 600 mg</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo 24 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>IMM-124E, 1200 mg</title>
            <description>IMM-124E, 1200 mg three times daily, orally 24 weeks of treatment</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo</title>
            <description>Matching placebo, three times daily, orally 24 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Adverse Events</title>
          <description>Number of grade 3-5 adverse events</description>
          <population>Number of grade 3-5 AEs</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Mean change in Systolic Blood Pressure</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>The analysis population include subjects with data of both baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Mean change in Systolic Blood Pressure</description>
          <population>The analysis population include subjects with data of both baseline and week 24</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="16.19"/>
                    <measurement group_id="O2" value="2.0" spread="12.73"/>
                    <measurement group_id="O3" value="0.2" spread="14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Rate</title>
        <description>Mean change in Pulse Rate from baseline to week 24</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>The analysis population include subjects with Pulse Rate data of both baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate</title>
          <description>Mean change in Pulse Rate from baseline to week 24</description>
          <population>The analysis population include subjects with Pulse Rate data of both baseline and week 24</population>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="10.91"/>
                    <measurement group_id="O2" value="-1.9" spread="9.29"/>
                    <measurement group_id="O3" value="2.1" spread="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>Change in Diastolic Blood Pressure</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>The analysis population include subjects with data of both baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Change in Diastolic Blood Pressure</description>
          <population>The analysis population include subjects with data of both baseline and week 24</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="11.17"/>
                    <measurement group_id="O2" value="-0.5" spread="6.40"/>
                    <measurement group_id="O3" value="-0.3" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Rate</title>
        <description>Mean change in Respiratory Rate from baseline to week 24</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>The analysis population includes subjects with both respiratory rate data at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Rate</title>
          <description>Mean change in Respiratory Rate from baseline to week 24</description>
          <population>The analysis population includes subjects with both respiratory rate data at baseline and week 24</population>
          <units>breaths/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.63"/>
                    <measurement group_id="O2" value="-0.3" spread="1.68"/>
                    <measurement group_id="O3" value="0.1" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Alanine Aminotransaminase (ALT)</title>
        <description>Mean change from Baseline in Serum Alanine Aminotransaminase (ALT) at Week 24</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Alanine Aminotransaminase (ALT)</title>
          <description>Mean change from Baseline in Serum Alanine Aminotransaminase (ALT) at Week 24</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="4.95"/>
                    <measurement group_id="O2" value="-10.7" spread="4.55"/>
                    <measurement group_id="O3" value="-10.3" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Serum Concentration (Cmax)</title>
        <description>Peak serum concentration (Cmax) of IMM-124E</description>
        <time_frame>0, 4, 12 and 24 Weeks</time_frame>
        <population>The investigational product is orally active and not systemically absorbed into the blood stream. This analysis purpose was to confirm this claim and show there is no absorption to blood stream.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Serum Concentration (Cmax)</title>
          <description>Peak serum concentration (Cmax) of IMM-124E</description>
          <population>The investigational product is orally active and not systemically absorbed into the blood stream. This analysis purpose was to confirm this claim and show there is no absorption to blood stream.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Serum Concentration (Cmin)</title>
        <description>Minimum serum concentration (Cmin) of IMM-124E</description>
        <time_frame>0, 4, 12 and 24 Weeks</time_frame>
        <population>The investigational product is orally active and not systemically absorbed into the blood stream. This analysis purpose was to confirm this claim and show there is no absorption to blood stream.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Serum Concentration (Cmin)</title>
          <description>Minimum serum concentration (Cmin) of IMM-124E</description>
          <population>The investigational product is orally active and not systemically absorbed into the blood stream. This analysis purpose was to confirm this claim and show there is no absorption to blood stream.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve (AUC)</title>
        <description>Area Under the Concentration Time Curve (AUC) of IMM-124E. Time points at which data were collected: baseline pre-dose, week 4, week 12 and week 24.</description>
        <time_frame>0, 4, 12 and 24 Weeks</time_frame>
        <population>The investigational product is orally active and not systemically absorbed into the blood stream. This analysis purpose was to confirm this claim and show there is no absorption to blood stream.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve (AUC)</title>
          <description>Area Under the Concentration Time Curve (AUC) of IMM-124E. Time points at which data were collected: baseline pre-dose, week 4, week 12 and week 24.</description>
          <population>The investigational product is orally active and not systemically absorbed into the blood stream. This analysis purpose was to confirm this claim and show there is no absorption to blood stream.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half Life (T1/2)</title>
        <description>Elimination Half Life (T1/2) of IMM-124E</description>
        <time_frame>0, 4, 12 and 24 Weeks</time_frame>
        <population>The investigational product is orally active and not systemically absorbed into the blood stream. This analysis purpose was to confirm this claim and show there is no absorption to blood stream.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half Life (T1/2)</title>
          <description>Elimination Half Life (T1/2) of IMM-124E</description>
          <population>The investigational product is orally active and not systemically absorbed into the blood stream. This analysis purpose was to confirm this claim and show there is no absorption to blood stream.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (BMI)</title>
        <description>Change from Baseline of Body Mass Index (BMI) at 24 weeks</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Change from Baseline of Body Mass Index (BMI) at 24 weeks</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="1.024"/>
                    <measurement group_id="O2" value="-0.33" spread="1.701"/>
                    <measurement group_id="O3" value="0.09" spread="1.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference</title>
        <description>Change from Baseline of Waist Circumference at 24 weeks</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference</title>
          <description>Change from Baseline of Waist Circumference at 24 weeks</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="4.353"/>
                    <measurement group_id="O2" value="-0.35" spread="5.969"/>
                    <measurement group_id="O3" value="-0.92" spread="6.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist:Hip Ratio</title>
        <description>Change from Baseline of Waist:Hip Ratio at 24 weeks</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Waist:Hip Ratio</title>
          <description>Change from Baseline of Waist:Hip Ratio at 24 weeks</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.051"/>
                    <measurement group_id="O2" value="0.01" spread="0.063"/>
                    <measurement group_id="O3" value="0.01" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin (HB)A1C</title>
        <description>Change from Baseline of Hemoglobin(HB)A1C at 24 weeks</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin (HB)A1C</title>
          <description>Change from Baseline of Hemoglobin(HB)A1C at 24 weeks</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.88"/>
                    <measurement group_id="O2" value="0.1" spread="0.84"/>
                    <measurement group_id="O3" value="0.2" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>Change from Baseline of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 24 weeks</description>
        <time_frame>baseline and 24 Weeks</time_frame>
        <population>HOMA-IR is calculated according to the formula: fasting insulin (mU/mL) x fasting glucose (mmol/L)/22.5</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>Change from Baseline of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 24 weeks</description>
          <population>HOMA-IR is calculated according to the formula: fasting insulin (mU/mL) x fasting glucose (mmol/L)/22.5</population>
          <units>no unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.098" spread="2.3374"/>
                    <measurement group_id="O2" value="0.057" spread="2.1340"/>
                    <measurement group_id="O3" value="0.655" spread="2.1648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol</title>
        <description>Change from Baseline of Total Cholesterol at 24 weeks</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <description>Change from Baseline of Total Cholesterol at 24 weeks</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.11"/>
                    <measurement group_id="O2" value="0.0" spread="0.10"/>
                    <measurement group_id="O3" value="0.0" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <description>Change from Baseline of Triglycerides at 24 weeks</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>Change from Baseline of Triglycerides at 24 weeks</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.25"/>
                    <measurement group_id="O2" value="-0.3" spread="1.15"/>
                    <measurement group_id="O3" value="-0.4" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Density Lipoprotein (LDL)</title>
        <description>Change from Baseline of Low Density Lipoprotein (LDL) at 24 weeks</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoprotein (LDL)</title>
          <description>Change from Baseline of Low Density Lipoprotein (LDL) at 24 weeks</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.09"/>
                    <measurement group_id="O2" value="0.1" spread="0.08"/>
                    <measurement group_id="O3" value="0.0" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein (HDL)</title>
        <description>Change from Baseline of High Density Lipoprotein (HDL) at 24 weeks</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein (HDL)</title>
          <description>Change from Baseline of High Density Lipoprotein (HDL) at 24 weeks</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.03"/>
                    <measurement group_id="O2" value="0.0" spread="0.02"/>
                    <measurement group_id="O3" value="0.1" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Alanine Aminotransaminase (ALT)</title>
        <description>Mean change from Baseline of serum ALT</description>
        <time_frame>baseline to 24 weeks</time_frame>
        <population>assessed at 0, 4, 8, 12, 16, 20 and 24 Weeks, change from baseline to week 24 reported</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Alanine Aminotransaminase (ALT)</title>
          <description>Mean change from Baseline of serum ALT</description>
          <population>assessed at 0, 4, 8, 12, 16, 20 and 24 Weeks, change from baseline to week 24 reported</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="4.95"/>
                    <measurement group_id="O2" value="-10.7" spread="4.55"/>
                    <measurement group_id="O3" value="-10.3" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Aspartate Aminotransaminase (AST)</title>
        <description>Mean change from Baseline of Serum AST</description>
        <time_frame>baseline to 24 Weeks</time_frame>
        <population>assessed at 0, 4, 8, 12, 16, 20 and 24 Weeks, change from baseline to week 24 reported</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Aspartate Aminotransaminase (AST)</title>
          <description>Mean change from Baseline of Serum AST</description>
          <population>assessed at 0, 4, 8, 12, 16, 20 and 24 Weeks, change from baseline to week 24 reported</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="3.32"/>
                    <measurement group_id="O2" value="-7.4" spread="3.05"/>
                    <measurement group_id="O3" value="-7.5" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin</title>
        <description>Mean change from Baseline of Bilirubin</description>
        <time_frame>baseline to 24 Weeks</time_frame>
        <population>assessed at 0, 4, 8, 12, 16, 20 and 24 Weeks, change from baseline to week 24 reported</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin</title>
          <description>Mean change from Baseline of Bilirubin</description>
          <population>assessed at 0, 4, 8, 12, 16, 20 and 24 Weeks, change from baseline to week 24 reported</population>
          <units>umol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="3.56"/>
                    <measurement group_id="O2" value="-1.0" spread="0.54"/>
                    <measurement group_id="O3" value="0.3" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albumin</title>
        <description>Mean change from Baseline of Albumin</description>
        <time_frame>baseline to 24 Weeks</time_frame>
        <population>assessed at 0, 4, 8, 12, 16, 20 and 24 Weeks, change from baseline to week 24 reported</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Albumin</title>
          <description>Mean change from Baseline of Albumin</description>
          <population>assessed at 0, 4, 8, 12, 16, 20 and 24 Weeks, change from baseline to week 24 reported</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.35"/>
                    <measurement group_id="O2" value="-0.2" spread="0.32"/>
                    <measurement group_id="O3" value="0.3" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gamma Glutamyl Transpeptidase (GGT)</title>
        <description>Mean change from Baseline of Gamma Glutamyl Transpeptidase (GGT)</description>
        <time_frame>baseline to 24 Weeks</time_frame>
        <population>assessed at 0, 4, 8, 12, 16, 20 and 24 Weeks, change from baseline to week 24 reported</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Gamma Glutamyl Transpeptidase (GGT)</title>
          <description>Mean change from Baseline of Gamma Glutamyl Transpeptidase (GGT)</description>
          <population>assessed at 0, 4, 8, 12, 16, 20 and 24 Weeks, change from baseline to week 24 reported</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="5.03"/>
                    <measurement group_id="O2" value="-9.7" spread="4.62"/>
                    <measurement group_id="O3" value="-5.7" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Alanine Aminotransaminase (ALT)</title>
        <description>Number of patients with ALT within the normal reference range at Week 24 (defined a &lt;19 IU/L for women and &lt;30 IU/L for men)</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Alanine Aminotransaminase (ALT)</title>
          <description>Number of patients with ALT within the normal reference range at Week 24 (defined a &lt;19 IU/L for women and &lt;30 IU/L for men)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Concentrations of Lipopolysaccharide (LPS)</title>
        <description>The percentage of subjects reporting at least 15% reduction in LPS, from baseline to Week 24</description>
        <time_frame>0, 4, 12 and 24 Weeks</time_frame>
        <population>excluding subjects with &lt; 250 LPS at baseline (comparing 1200mg IMP group to Placebo group). PP population, excluding outliers sites. this Outcome Measure was pre-specified to be assessed in the 1200mg and Placebo Arms/Groups *only*</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Lipopolysaccharide (LPS)</title>
          <description>The percentage of subjects reporting at least 15% reduction in LPS, from baseline to Week 24</description>
          <population>excluding subjects with &lt; 250 LPS at baseline (comparing 1200mg IMP group to Placebo group). PP population, excluding outliers sites. this Outcome Measure was pre-specified to be assessed in the 1200mg and Placebo Arms/Groups *only*</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regulatory T Cells (FoxP3+ CD25-CD4+) in Peripheral Blood Mononuclear Cells</title>
        <description>Change in percent of FoxP3+ CD25-CD4+ cells in Peripheral Blood Mononuclear Cells</description>
        <time_frame>0 and 24 Weeks</time_frame>
        <population>Sub group population with PBMC FACS data, selected sites only.</population>
        <group_list>
          <group group_id="O1">
            <title>IMM-124E, 600 mg</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo 24 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>IMM-124E, 1200 mg</title>
            <description>IMM-124E, 1200 mg three times daily, orally 24 weeks of treatment</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo</title>
            <description>Matching placebo, three times daily, orally 24 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Regulatory T Cells (FoxP3+ CD25-CD4+) in Peripheral Blood Mononuclear Cells</title>
          <description>Change in percent of FoxP3+ CD25-CD4+ cells in Peripheral Blood Mononuclear Cells</description>
          <population>Sub group population with PBMC FACS data, selected sites only.</population>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">only 1 participant's data analyzed in 600mg arm.</measurement>
                    <measurement group_id="O2" value="0.46" spread="0.26"/>
                    <measurement group_id="O3" value="14.59" spread="14.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Gut Microbiome From Fecal Samples</title>
        <description>Number of participants with measurable differences in gut microbiome constituents post-treatment</description>
        <time_frame>0, 4, 12 and 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Gut Microbiome From Fecal Samples</title>
          <description>Number of participants with measurable differences in gut microbiome constituents post-treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Concentrations of LPS</title>
        <description>Serum Concentrations of Lipopolysaccharide (LPS) (ng/mL) levels and change from Baseline</description>
        <time_frame>baseline to 24 Weeks</time_frame>
        <population>assessed at 0, 4, 12 and 24 Weeks, change from baseline to week 24 reported</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of LPS</title>
          <description>Serum Concentrations of Lipopolysaccharide (LPS) (ng/mL) levels and change from Baseline</description>
          <population>assessed at 0, 4, 12 and 24 Weeks, change from baseline to week 24 reported</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-130.763" spread="188.153"/>
                    <measurement group_id="O2" value="78.488" spread="173.029"/>
                    <measurement group_id="O3" value="414.912" spread="182.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Concentrations of C-Reactive Protein (CRP)</title>
        <description>Mean Serum Concentrations of C-Reactive Protein (CRP) at week 24</description>
        <time_frame>baseline to 24 Weeks</time_frame>
        <population>assessed at 0, 4, 12 and 24 Weeks, change from baseline to week 24 reported</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of C-Reactive Protein (CRP)</title>
          <description>Mean Serum Concentrations of C-Reactive Protein (CRP) at week 24</description>
          <population>assessed at 0, 4, 12 and 24 Weeks, change from baseline to week 24 reported</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.711" spread="0.68"/>
                    <measurement group_id="O2" value="1.129" spread="1.637"/>
                    <measurement group_id="O3" value="1.364" spread="2.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Concentrations of CK-18 Fragments</title>
        <description>The proportion of subjects with significant reduction of CK-18 (≥ 15%) between IMP 1200mg group to placebo.</description>
        <time_frame>baseline to 24 weeks</time_frame>
        <population>FAS population, excluding outlier sites. this Outcome Measure was pre-specified to be assessed in the 1200mg and Placebo Arms/Groups *only*</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of CK-18 Fragments</title>
          <description>The proportion of subjects with significant reduction of CK-18 (≥ 15%) between IMP 1200mg group to placebo.</description>
          <population>FAS population, excluding outlier sites. this Outcome Measure was pre-specified to be assessed in the 1200mg and Placebo Arms/Groups *only*</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Concentrations of Human Adiponectin</title>
        <description>Change from Run-in to Post-treatment in serum concentration of human Adiponectin.</description>
        <time_frame>0 to 24 Weeks</time_frame>
        <population>ITT population. Run-in = mean of screening and baseline values. assessed at 0, 4, 12 and 24 Weeks, change from baseline to week 24 reported</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Human Adiponectin</title>
          <description>Change from Run-in to Post-treatment in serum concentration of human Adiponectin.</description>
          <population>ITT population. Run-in = mean of screening and baseline values. assessed at 0, 4, 12 and 24 Weeks, change from baseline to week 24 reported</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107560.15" spread="1082735.0"/>
                    <measurement group_id="O2" value="208185.48" spread="1115352.8"/>
                    <measurement group_id="O3" value="1082735.0" spread="1900710.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Concentrations of Cytokine IL-6</title>
        <description>Mean Change from baseline to week 24 of serum concentration of cytokine IL-6</description>
        <time_frame>24 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Cytokine IL-6</title>
          <description>Mean Change from baseline to week 24 of serum concentration of cytokine IL-6</description>
          <population>ITT population</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1234" spread="0.90505"/>
                    <measurement group_id="O2" value="0.1031" spread="1.63948"/>
                    <measurement group_id="O3" value="0.4117" spread="1.50248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Concentration of Cytokine IL-12p70</title>
        <description>Mean change from baseline to week 24 of Serum concentration of Cytokine IL-12p70</description>
        <time_frame>24 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of Cytokine IL-12p70</title>
          <description>Mean change from baseline to week 24 of Serum concentration of Cytokine IL-12p70</description>
          <population>ITT population</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0494" spread="1.00060"/>
                    <measurement group_id="O2" value="0.3274" spread="2.76062"/>
                    <measurement group_id="O3" value="0.0579" spread="1.35852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Concentration of Interferon Gamma (IFN-γ)</title>
        <description>Mean Change from baseline to week 24 of serum concentration of IFN-gamma</description>
        <time_frame>24 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of Interferon Gamma (IFN-γ)</title>
          <description>Mean Change from baseline to week 24 of serum concentration of IFN-gamma</description>
          <population>ITT population</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9523" spread="6.25581"/>
                    <measurement group_id="O2" value="0.8058" spread="6.59164"/>
                    <measurement group_id="O3" value="1.4514" spread="7.56336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Concentration of Tumor Necrosis Factor Alpha (TNF-α)</title>
        <description>Mean Change from baseline to week 24 of serum concentration of TNF-α</description>
        <time_frame>24 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of Tumor Necrosis Factor Alpha (TNF-α)</title>
          <description>Mean Change from baseline to week 24 of serum concentration of TNF-α</description>
          <population>ITT population</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1691" spread="1.68068"/>
                    <measurement group_id="O2" value="-0.5082" spread="1.59892"/>
                    <measurement group_id="O3" value="-0.3877" spread="2.16469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Concentration of Glucagon-like Peptide-1 (GLP-1)</title>
        <description>Mean Change from baseline to week 24 of serum concentration of GLP-1</description>
        <time_frame>24 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>IMM-124E, 1200 mg three times daily, orally
IMM-124E: IMM-124E</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Matching placebo, three times daily, orally
Placebo: Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of Glucagon-like Peptide-1 (GLP-1)</title>
          <description>Mean Change from baseline to week 24 of serum concentration of GLP-1</description>
          <population>ITT population</population>
          <units>pM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6457" spread="15.79917"/>
                    <measurement group_id="O2" value="-1.5310" spread="13.07262"/>
                    <measurement group_id="O3" value="3.4820" spread="33.36977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regulatory T Cells (FoxP3+CD25-CD8+) in Peripheral Blood Mononuclear Cells</title>
        <description>Change in percent of FoxP3+CD25-CD8+ cells in Peripheral Blood Mononuclear Cells</description>
        <time_frame>0 and 24 Weeks</time_frame>
        <population>Sub group population with PBMC FACS data, selected sites only.</population>
        <group_list>
          <group group_id="O1">
            <title>IMM-124E, 600 mg</title>
            <description>IMM-124E, 600 mg three times daily, orally plus matching placebo 24 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>IMM-124E, 1200 mg</title>
            <description>IMM-124E, 1200 mg three times daily, orally 24 weeks of treatment</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo</title>
            <description>Matching placebo, three times daily, orally 24 weeks of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Regulatory T Cells (FoxP3+CD25-CD8+) in Peripheral Blood Mononuclear Cells</title>
          <description>Change in percent of FoxP3+CD25-CD8+ cells in Peripheral Blood Mononuclear Cells</description>
          <population>Sub group population with PBMC FACS data, selected sites only.</population>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">only 1 participant's data analyzed in 600mg arm.</measurement>
                    <measurement group_id="O2" value="-0.01" spread="0.33"/>
                    <measurement group_id="O3" value="12.52" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 weeks after participant received first dose</time_frame>
      <desc>The adverse event information collected in the clinical study is collected based on the adverse event definition of ''Results Data Element Definitions for Adverse Events''.
The adverse events data was collected based on physician's assessments, laboratory assessments, subjects reporting and questionnaires.</desc>
      <group_list>
        <group group_id="E1">
          <title>IMM-124E, 600 mg</title>
          <description>IMM-124E, 600 mg three times daily, orally plus matching placebo 24 weeks of treatment</description>
        </group>
        <group group_id="E2">
          <title>IMM-124E, 1200 mg</title>
          <description>IMM-124E, 1200 mg three times daily, orally 24 weeks of treatment</description>
        </group>
        <group group_id="E3">
          <title>Matching Placebo</title>
          <description>Matching placebo, three times daily, orally 24 weeks of treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <description>Psychiatric hospitalisation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="46"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E2" events="17" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>lower and/or upper</description>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neta Tobis, Clinical Director</name_or_title>
      <organization>Immuron</organization>
      <phone>+972549277334 ext 2549277334</phone>
      <email>neta@immuron.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

